LGND - Ligand Pharmaceuticals Inc Stock Price, Fair Value and News

79.01USD-0.91 (-1.14%)Market Closed

Market Summary

USD79.01-0.91

Market Closed

-1.14%

LGND Stock Price

View Fullscreen

LGND RSI Chart

LGND Valuation

Market Cap

1.4B

Price/Earnings (Trailing)

27.13

Price/Sales (Trailing)

10.78

EV/EBITDA

13.8

Price/Free Cashflow

30.72

LGND Price/Sales (Trailing)

LGND Profitability

EBT Margin

48.48%

Return on Equity

7.44%

Return on Assets

6.63%

Free Cashflow Yield

3.25%

LGND Fundamentals

LGND Revenue

Revenue (TTM)

131.3M

Rev. Growth (Yr)

-44.22%

Rev. Growth (Qtr)

-14.5%

LGND Earnings

Earnings (TTM)

52.2M

Earnings Growth (Yr)

204.02%

Earnings Growth (Qtr)

277.05%

Breaking Down LGND Revenue

Last 7 days

-1.9%

Last 30 days

12.4%

Last 90 days

12.8%

Trailing 12 Months

5.6%

How does LGND drawdown profile look like?

LGND Financial Health

Current Ratio

14.15

LGND Investor Care

Shares Dilution (1Y)

3.68%

Diluted EPS (TTM)

2.92

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	203.7M	179.9M	153.6M	131.3M
2022	231.5M	202.7M	202.3M	196.2M
2021	199.8M	237.3M	255.1M	241.5M
2020	110.0M	126.4M	143.4M	186.4M
2019	238.8M	173.7M	152.9M	120.3M
2018	251.5M	251.5M	251.5M	251.5M
2017	135.5M	206.0M	230.0M	251.5M
2016	87.0M	88.1M	92.0M	109.0M
2015	63.2M	71.0M	73.7M	71.9M
2014	53.3M	54.3M	56.3M	64.5M
2013	37.4M	41.2M	47.9M	49.0M
2012	31.8M	30.1M	30.7M	31.4M
2011	21.5M	23.1M	21.0M	30.0M
2010	0	33.8M	28.7M	23.5M
2009	0	0	0	38.9M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Ligand Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 25, 2024	davis todd c	acquired	919,147	57.3929	16,015	chief executive officer
Mar 05, 2024	sabba stephen l	sold	-140,650	74.3	-1,893	-
Mar 05, 2024	sabba stephen l	acquired	-	-	2,893	-
Mar 05, 2024	aryeh jason	acquired	113,840	39.35	2,893	-
Feb 28, 2024	espinoza octavio	sold	-12,384	88.46	-140	chief financial officer
Feb 28, 2024	espinoza octavio	acquired	71,564	56.6173	1,264	chief financial officer
Feb 27, 2024	espinoza octavio	acquired	-	-	7,208	chief financial officer
Feb 27, 2024	davis todd c	acquired	-	-	32,436	chief executive officer
Feb 27, 2024	reardon andrew	acquired	-	-	7,208	chief legal officer &
Feb 27, 2024	korenberg matthew e	acquired	-	-	14,416	president & chief operating

Which funds bought or sold LGND recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 15, 2024	Chicago Capital, LLC	reduced	-0.83	248,952	16,783,500	0.51%
Apr 15, 2024	Legato Capital Management LLC	added	4.84	15,525	227,999	0.03%
Apr 12, 2024	Financial Synergies Wealth Advisors, Inc.	new	-	951	951	-%
Apr 11, 2024	BTC Capital Management, Inc.	new	-	336,629	336,629	0.03%
Apr 09, 2024	MATHER GROUP, LLC.	new	-	286	286	-%
Apr 09, 2024	WOODSTOCK CORP	unchanged	-	50,586	2,201,110	0.23%
Apr 09, 2024	MASSMUTUAL TRUST CO FSB/ADV	unchanged	-	145	6,287	-%
Apr 05, 2024	CWM, LLC	reduced	-25.57	-7,000	21,000	-%
Apr 05, 2024	GAMMA Investing LLC	reduced	-29.69	-4,953	11,769	-%
Apr 02, 2024	M&R CAPITAL MANAGEMENT INC	new	-	146,200	146,200	0.04%

Are Funds Buying or Selling LGND?

Are funds buying LGND calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LGND

No. of Funds

Unveiling Ligand Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	macquarie group ltd	5.66%	987,248	SC 13G
Feb 13, 2024	janus henderson group plc	7.7%	1,343,154	SC 13G/A
Feb 13, 2024	vanguard group inc	10.76%	1,876,514	SC 13G/A
Feb 12, 2024	goldman sachs group inc	6.8%	1,181,931	SC 13G
Jan 22, 2024	blackrock inc.	17.0%	2,962,094	SC 13G/A
Feb 10, 2023	janus henderson group plc	7.4%	1,255,273	SC 13G/A
Feb 09, 2023	william blair investment management, llc	0.8%	141,128	SC 13G/A
Feb 09, 2023	vanguard group inc	10.91%	1,843,115	SC 13G/A
Feb 06, 2023	state street corp	3.85%	649,914	SC 13G/A
Jan 26, 2023	blackrock inc.	16.5%	2,789,479	SC 13G/A

Recent SEC filings of Ligand Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Mar 27, 2024	4	Insider Trading
Mar 07, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading
Mar 05, 2024	144	Notice of Insider Sale Intent
Mar 01, 2024	S-8	Employee Benefits Plan
Feb 29, 2024	10-K	Annual Report
Feb 29, 2024	144/A	144/A
Feb 29, 2024	4	Insider Trading
Feb 29, 2024	4	Insider Trading
Feb 29, 2024	4	Insider Trading

Peers (Alternatives to Ligand Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.7B	6.8B	-0.04%	-27.89%	-8.41	5.79	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.5B	1.8B	-1.63%	-28.69%	-42.01	10.12	76.23%	61.08%
BMRN	17.2B	2.4B	8.39%	-9.36%	102.31	7.09	15.42%	18.43%
INCY	11.9B	3.7B	-8.82%	-29.04%	20	3.23	8.87%	75.42%
MID-CAP
APLS	6.2B	396.6M	-8.69%	-36.86%	-11.82	15.75	425.83%	18.94%
BBIO	4.4B	-	-8.20%	68.33%	-6.81	60.35	54.84%	-34.79%
AXSM	3.3B	270.6M	-8.92%	-2.36%	-13.62	12.04	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.30%	-24.47%	-9.88	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.52%	-11.77%	-45.95	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-3.36%	-14.10%	25.63	4.6	85.90%	-14.05%
NVAX	557.0M	983.7M	-24.76%	-57.93%	-1.02	0.57	-50.36%	17.16%
CRBP	432.8M	881.7K	-5.56%	294.36%	-9.7	466.16	-77.61%	-5.33%
INO	225.3M	4.9M	-10.24%	-14.54%	-1.67	46.29	-54.97%	51.72%
IBIO	6.8M	2.1M	86.67%	92.16%	-0.25	2.14	-13.45%	66.37%

Ligand Pharmaceuticals Inc News

Latest updates

Ligand Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-14.5%	28.00	33.00	26.00	44.00	50.00	59.00	50.00	37.00	56.00	60.00	79.00	47.00	70.00	42.00	41.00	33.00	27.00	25.00	25.00	43.00	60.00
Operating Expenses	-1.4%	31.00	32.00	28.00	30.00	70.00	47.00	41.00	34.00	41.00	35.00	25.00	37.00	76.00	38.00	34.00	29.00	37.00	30.00	29.00	30.00	26.00
S&GA Expenses	9.1%	16.00	15.00	11.00	11.00	31.00	15.00	12.00	12.00	13.00	11.00	12.00	11.00	26.00	15.00	10.00	9.00	10.00	10.00	11.00	11.00	11.00
R&D Expenses	-0.8%	5.00	6.00	7.00	7.00	9.00	9.00	8.00	9.00	8.00	7.00	7.00	9.00	3.00	13.00	13.00	12.00	19.00	14.00	12.00	11.00	9.00
EBITDA Margin	7.0%	0.77*	0.72*	0.78*	0.73*	0.46*	0.44*	0.47*	0.54*	0.59*	0.56*	0.46*	0.49*	-	-	-	-	-	-	-	-	-
Interest Expenses	13000.0%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	4.00	4.00	5.00	6.00	6.00	6.00	6.00	9.00	9.00	9.00	9.00	9.00	20.00
Income Taxes	41.7%	-1.09	-1.87	1.00	12.00	39.00	3.00	-3.94	4.00	4.00	2.00	3.00	-12.34	-2.39	-4.91	6.00	-6.28	-0.81	-4.62	-3.61	176	-14.31
Earnings Before Taxes	240.8%	17.00	-12.14	3.00	56.00	24.00	12.00	9.00	-9.14	18.00	15.00	33.00	6.00	15.00	-11.61	28.00	-30.41	-8.18	-19.87	-18.03	843	-56.79
EBT Margin	5.3%	0.48*	0.46*	0.53*	0.49*	0.18*	0.15*	0.16*	0.25*	0.30*	0.27*	0.18*	0.19*	-	-	-	-	-	-	-	-	-
Net Income	277.0%	18.00	-10.27	2.00	42.00	-17.48	0.00	-0.89	-15.38	-5.42	14.00	31.00	18.00	6.00	-6.70	22.00	-24.13	-7.36	-15.25	-14.42	666	-42.48
Net Income Margin	270.1%	0.40*	0.11*	0.15*	0.12*	-0.17*	-0.11*	-0.04*	0.10*	0.24*	0.27*	0.20*	0.20*	-	-	-	-	-	-	-	-	-
Free Cashflow	6.8%	8.00	7.00	-0.28	32.00	51.00	16.00	5.00	47.00	25.00	18.00	19.00	7.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	2.3%	787	769	758	811	763	1,051	1,076	1,105	1,298	1,274	1,256	1,295	1,362	1,247	1,243	1,186	1,495	1,547	1,802	1,914	1,261
Current Assets	-6.5%	237	254	277	328	264	220	244	276	465	432	411	437	501	858	864	831	1,124	1,183	1,442	1,568	871
Cash Equivalents	19.1%	23.00	19.00	28.00	89.00	45.00	4.00	5.00	15.00	20.00	23.00	22.00	32.00	48.00	457	116	118	72.00	226	274	107	120
Inventory	-5.6%	24.00	25.00	27.00	14.00	13.00	22.00	25.00	26.00	27.00	33.00	40.00	37.00	26.00	13.00	4.00	7.00	7.00	7.00	10.00	12.00	7.00
Net PPE	-3.5%	16.00	16.00	11.00	12.00	12.00	33.00	31.00	25.00	13.00	19.00	18.00	17.00	13.00	7.00	8.00	7.00	7.00	6.00	6.00	6.00	5.00
Goodwill	5551.7%	103	2.00	106	106	106	-	181	181	-	190	191	191	190	82.00	103	9.00	95.00	94.00	88.00	87.00	87.00
Liabilities	-14.8%	86.00	101	93.00	165	165	234	274	312	476	462	470	549	653	550	548	524	728	697	760	834	700
Current Liabilities	6.7%	17.00	16.00	29.00	99.00	99.00	135	168	43.00	42.00	36.00	52.00	96.00	100	42.00	29.00	20.00	17.00	36.00	109	187	82.00
Long Term Debt	-	-	-	-	-	-	-	-	177	321	317	315	352	442	455	450	444	639	632	624	617	610
LT Debt, Current	-	-	-	-	77.00	77.00	77.00	115	-	-	-	-	-	-	-	-	-	-	-	27.00	27.00	26.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	177	321	317	315	352	442	455	450	444	639	632	624	617	610
Shareholder's Equity	4.9%	701	668	665	646	597	816	802	793	821	812	787	746	710	698	695	662	767	851	1,041	1,080	561
Retained Earnings	3.8%	503	485	495	493	451	468	468	469	449	455	441	410	392	386	393	371	400	407	423	437	-229
Additional Paid-In Capital	8.0%	199	184	171	154	148	349	335	325	373	358	347	337	318	313	304	296	367	445	619	643	791
Shares Outstanding	0.8%	18.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	16.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	900	-	-	-	1,000	-	-	-	1,800	-	-	-	1,200	-	-	-	1,800	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	5.5%	8,065	7,646	-82.00	33,948	53,472	20,489	11,878	52,011	27,642	20,025	20,377	10,754	537	12,745	24,382	16,922	-7,339	-6,197	-61,058	45,258	32,572
Share Based Compensation	-16.9%	5,721	6,884	7,207	5,931	29,145	12,597	9,499	9,044	10,408	9,754	10,216	8,405	9,975	7,740	7,359	5,653	6,300	6,297	6,571	5,347	6,009
Cashflow From Investing	47.3%	-10,284	-19,503	7,556	10,549	-7,284	19,176	37,851	113,881	-35,713	-18,217	19,338	65,115	-382,202	332,071	-26,757	308,536	-63,179	169,517	265,803	94,777	275,302
Cashflow From Financing	62.5%	5,315	3,270	-67,757	-775	-5,298	-40,829	-59,442	-170,421	4,164	-385	-49,905	-91,635	-27,529	-3,706	-5.00	-279,305	-83,693	-211,312	-37,591	-152,576	-347,085
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	4,711	-	-	73,287	84,250	181,188	33,717	151,585	70,141

LGND Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Total revenues	$ 131,314	$ 196,245	$ 241,544
Operating costs and expenses:
Cost of Captisol	10,512	52,827	62,176
Amortization of intangibles	33,654	34,237	34,222
Research and development	24,537	36,082	32,105
General and administrative	52,790	70,062	46,790
Other operating income	0	0	(37,600)
Total operating costs and expenses	121,493	193,208	137,693
Gain on sale of Pelican	(2,121)	0	0
Income from continuing operations	11,942	3,037	103,851
Other income (expense):
Gain (loss) from short-term investments	46,365	28,540	(5,263)
Interest income	7,711	2,046	886
Interest expense	(656)	(1,799)	(19,619)
Gain on derivative instruments	250	0	0
Other income (expense), net	(1,952)	4,187	(7,650)
Total other income (expense), net	51,718	32,974	(31,646)
Income before income tax from continuing operations	63,660	36,011	72,205
Income tax benefit (expense)	(9,841)	(41,230)	4,148
Net income (loss) from continuing operations	53,819	(5,219)	76,353
Net loss from discontinued operations	(1,665)	(28,142)	(19,215)
Net income (loss):	$ 52,154	$ (33,361)	$ 57,138
Basic net income (loss) from continuing operations (in USD per share)	$ 3.11	$ (0.31)	$ 4.59
Basic net loss from discontinued operations (in USD per share)	(0.10)	(1.67)	(1.16)
Basic net income (loss) per share (in USD per share)	$ 3.02	$ (1.98)	$ 3.44
Shares used in basic per share calculation (in shares)	17,298	16,868	16,630
Diluted net income (loss) from continuing operations (in USD per share)	$ 3.03	$ (0.31)	$ 4.43
Diluted net loss from discontinued operations (in USD per share)	(0.09)	(1.67)	(1.11)
Diluted net income (loss) per share (in USD per share)	$ 2.94	$ (1.98)	$ 3.31
Shares used in diluted per share calculation (in shares)	17,757	16,868	17,246
Royalties
Revenues:
Total revenues	$ 83,910	$ 72,527	$ 48,927
Captisol
Revenues:
Total revenues	28,372	104,495	164,250
Contract
Revenues:
Total revenues	$ 19,032	$ 19,223	$ 28,367

LGND Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 22,954	$ 45,006
Short-term investments	147,355	166,864
Accounts receivable, net	32,917	30,424
Inventory	23,969	13,294
Income taxes receivable	6,395	4,614
Prepaid expenses	1,182	1,132
Other current assets	2,657	2,267
Total current assets	237,429	263,601
Deferred income taxes, net	214	8,530
Intangible assets, net	299,606	342,455
Goodwill	103,370	105,673
Commercial license and other economic rights	67,291	10,182
Property and equipment, net	15,607	12,482
Operating lease assets	6,062	10,914
Finance lease assets	3,393	4,095
Equity method investment in Primrose Bio	12,595	0
Other investments	35,726	3,000
Other assets	5,923	1,736
Total assets	787,216	762,668
Current liabilities:
Accounts payable	2,427	5,307
Accrued liabilities	12,467	15,681
Current contingent liabilities	256	57
Deferred revenue	1,222	355
Current operating lease liabilities	403	670
Current finance lease liabilities	7	45
2023 convertible senior notes, net	0	76,695
Total current liabilities	16,782	98,810
Long-term deferred revenue	1,444	44
Long-term contingent liabilities	2,942	3,456
Deferred income taxes, net	31,622	30,615
Long-term operating lease liabilities	5,755	10,336
Other long-term liabilities	27,758	21,922
Total liabilities	86,303	165,183
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000 shares authorized; zero issued and outstanding at December 31, 2023 and 2022	0	0
Common stock, $0.001 par value; 60,000 shares authorized; 17,556 and 16,951 shares issued and outstanding at December 31, 2023 and 2022, respectively	18	17
Additional paid-in capital	198,696	147,590
Accumulated other comprehensive loss	(817)	(984)
Retained earnings	503,016	450,862
Total stockholders’ equity	700,913	597,485
Total liabilities and stockholders’ equity	$ 787,216	$ 762,668

About Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in San Diego, California.

CEO	Mr. Todd C. Davis Ph.D.
WEBSITE	ligand.com
INDUSTRY	Biotechnology
EMPLOYEES	76

Ligand Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Ligand Pharmaceuticals Inc? What does LGND stand for in stocks?

LGND is the stock ticker symbol of Ligand Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ligand Pharmaceuticals Inc (LGND)?

As of Tue Apr 16 2024, market cap of Ligand Pharmaceuticals Inc is 1.42 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LGND stock?

You can check LGND's fair value in chart for subscribers.

What is the fair value of LGND stock?

You can check LGND's fair value in chart for subscribers. The fair value of Ligand Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ligand Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LGND so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ligand Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether LGND is over valued or under valued. Whether Ligand Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Ligand Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LGND.

What is Ligand Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 16 2024, LGND's PE ratio (Price to Earnings) is 27.13 and Price to Sales (PS) ratio is 10.78. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LGND PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Ligand Pharmaceuticals Inc's stock?

In the past 10 years, Ligand Pharmaceuticals Inc has provided 0.022 (multiply by 100 for percentage) rate of return.